Aims to maximise total return comprising both capital growth and income, with an income yeild in excess of the FTSE All-Share Index.
Name | % Net Assets |
---|---|
HSBC Holdings Plc | 8.1% |
BP Plc | 7.7% |
GlaxoSmithKline Plc | 7.0% |
AstraZeneca Plc | 5.2% |
Vodafone Group Plc | 5.2% |
Daily Mail And General Trust Plc | 4.0% |
Rsa Insurance Group Plc | 3.7% |
Unilever Plc | 3.6% |
Next Plc | 3.0% |
Tomkins Plc | 2.9% |
Key | % Net Assets |
---|---|
HSBC Holdings Plc | 8.1% |
BP Plc | 7.7% |
GlaxoSmithKline Plc | 7.0% |
AstraZeneca Plc | 5.2% |
Other | 72% |
Date | 21-Oct-2022 |
---|---|
Bid | 454.70p |
Offer | 478.60p |
Currency | GBP |
Change | -4.10p |
% | -0.87% |
YTD change | 466.65p |
YTD % | n/a |
Fund Inception | 03/02/1997 |
---|---|
Fund Manager | n/a |
TER | 1.69 |
Minimum Investment | |
---|---|
Initial | £1500 |
Additional | n/a |
Savings | £500 |
Charges | |
---|---|
Initial | 5.00% |
Annual Mang't | 1.50% |
Exit | n/a |
Name | % |
---|---|
Standard deviation | 0.01 |
Sharpe ratio | 0.12 |
You are here: research